跳至主要内容
临床试验/CTRI/2025/09/094009
CTRI/2025/09/094009尚未招募不适用

Utilization of restricted antibiotics in culture positive and culture negative sepsis a prospective observational study

Apollo hospitals1 个研究点 分布在 1 个国家目标入组 251 人开始时间: 2025年9月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
251
试验地点
1
主要终点
To compare the defined daily dosage of restricted antibiotics administered to culture positive and culture negative sepsis.

研究概览

简要总结

To compare the defined daily dosage of restricted antibiotics which includes carbapenem polymyxin tigecyclin ceftazidime avibactum aztreonem teicoplanin in culture positive and culture negative sepsis with primary outcome as mentioned above and secondary outcome of  to explore the reasons for non de escalation of restricted antibiotics and to evaluate the role of biomarkers and infectious disease specialist in de escalation of restricted antibiotics in patients getting admitted into our multi disciplinary critical care unit over a period of three months a prospective observational study.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 85.00 Year(s)(—)
性别
All

入选标准

  • All patients aged more than 18 years who are receiving restricted antibiotics which includes Carbapenem polymyxin tigecyclin ceftazidime avibactum aztreonem teicoplanin at our multi disciplinary critical care unit.

排除标准

  • Patients who are not receiving restricted antibiotics.
  • Patients discharged or deceased within 24 hours of antibiotic initiation.

结局指标

主要结局

To compare the defined daily dosage of restricted antibiotics administered to culture positive and culture negative sepsis.

时间窗: Third day and seventh day

次要结局

  • To explore the reasons for non de escalation of restricted antibiotics in both groups(To evaluate the utility of biomarkers such as pro calcitonin in guiding de escalation.)

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

K Gunasri

Apollo hospitals

研究点 (1)

Loading locations...

相似试验